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Abstract
Background Stromal fibroblasts can contribute to tumor
invasion through the release of matrix metalloproteinases
(MMPs). Population studies have suggested that single
nucleotide polymorphisms (SNPs) in MMP genes influence
levels of expression and may be associated with breast cancer
risk and with disease progression. This study directly examined
the impact of MMP SNP genotype on the ability of host
fibroblasts to promote tumor cell invasion.
Methods Primary breast fibroblasts were isolated from patients
with (n = 13) or without (n = 19) breast cancer, and their ability
to promote breast cancer cell invasion was measured in in vitro
invasion assays. Fibroblast invasion-promoting capacity (IPC)
was analyzed in relation to donor type (tumor or non-tumor
patient), MMP-1, MMP-3, and MMP-9 SNP genotype and MMP
activity using independent samples t  test and analysis of
variance. All statistical tests were two-sided.
Results Tumor-derived fibroblasts promoted higher levels of
invasion than normal fibroblasts (p = 0.041). When IPC was
related to genotype, higher levels of IPC were generated by
tumor fibroblasts with the high-expressing MMP-3  5A/5A
genotype compared with the 5A/6A and 6A/6A genotypes (p =
0.05 and 0.07, respectively), and this was associated with
enhanced MMP-3 release. The functional importance of MMP-3
was demonstrated by enhanced invasion in the presence of
recombinant MMP-3, whereas reduction occurred in the
presence of a specific MMP-3 inhibitor. An inverse relationship
was demonstrated between fibroblast IPC and the high-
expressing MMP-1 genotype (p = 0.031), but no relationship
was seen with MMP-9  SNP status. In contrast, normal
fibroblasts showed no variation in IPC in relation to MMP
genotype, with MMP-3 5A/5A fibroblasts exhibiting significantly
lower levels of IPC than their tumor-derived counterparts (p =
0.04).
Conclusion This study has shown that tumor-derived fibroblasts
exhibit higher levels of IPC than normal fibroblasts and that the
MMP-3 5A/5A genotype contributes to this through enhanced
MMP-3 release. Despite a high-expressing genotype, normal
fibroblasts do not exhibit higher IPC or enhanced MMP release.
This suggests that more complex changes occur in tumor-
derived fibroblasts, enabling full expression of the MMP SNP
genotype and these possibly are epigenetic in nature. The
results do suggest that, in women with breast cancer, a high-
expressing MMP-3 genotype may promote tumor progression
more effectively.
bp = base pairs; CI = confidence interval; CM = conditioned media; DMEM = Dulbecco's modified Eagle's medium; dPBS = Dulbecco's phosphate-
buffered saline; EMA = epithelial membrane antigen; FBS = fetal bovine serum; IPC = invasion-promoting capacity; MMP = matrix metalloproteinase; 
OR = odds ratio; PCR = polymerase chain reaction; RT-PCR = reverse transcription-polymerase chain reaction; SMA = smooth muscle actin; SNP 
= single nucleotide polymorphism; TAF = tumor-associated fibroblast.Breast Cancer Research    Vol 9 No 5    Holliday et al.
Page 2 of 12
(page number not for citation purposes)
Introduction
The microenvironment plays a central role in controlling both
normal and transformed cell function as well as normal tissue
integrity [1]. Both in vitro studies and animal models have
demonstrated the importance of interactions with the microen-
vironment in modulating tumor progression [2]. Restoration of
normal microenvironment signalling has been shown to revert
features of the malignant phenotype, even when the tumor
cells retain their mutations [3,4]. Inflammatory cells, endothe-
lial cells, and stromal fibroblasts all are implicated in this activ-
ity. However, a number of studies have indicated a dominant
role for fibroblasts in modulating epithelial cell function, in pro-
moting tumor cell progression, and even in initiating epithelial
cell tumorigenesis [5-10].
Differences in the pattern of gene and protein expression have
been identified between peri-tumoral fibroblasts and their nor-
mal counterparts [2,11]. Such differences generally are
regarded as a stromal response to tumor-derived signals,
which then influence the tumor-promoting activity of the
stroma. For example, tumor-derived transforming growth fac-
tor-beta induces stromal hepatocyte growth factor which then,
in a paracrine fashion, promotes tumor cell invasion [12].
Emerging evidence also suggests that stroma may undergo
independent genetic and epigenetic modifications [13-16].
Although the functional implications of these alterations have
not been established fully, such changes may be expected to
contribute to altered stromal cell function and the generation
of a permissive tumor microenvironment. In contrast to such
acquired genetic alterations, the potential functional impact of
intrinsic genetic differences in stromal populations has
received less attention. A number of reports have indicated
that non-tumor fibroblasts from women with breast cancer dif-
fer from those isolated from women without breast cancer
[17,18]. It has been suggested that this could be an important
factor in defining the diversity of tumor behavior between indi-
viduals [14].
One way in which breast fibroblasts influence tumor behavior
is through the release and activation of matrix metalloprotein-
ases (MMPs) [19]. Several MMPs have been implicated as
having a role in breast cancer, including MMP-1, MMP-2,
MMP-3, and MMP-9, among others [20-22]. Common func-
tional promoter single nucleotide polymorphisms (SNPs) have
been described in some of these genes in which they have the
potential to influence levels of gene expression [23,24]. In
MMP-1, the polymorphism is characterized by an insertion
(2G) or deletion (1G) of a single guanine residue at -1607
base pairs (bp). The insertion of a G residue in the 2G allele
forms a binding site for the Ets-1 transcription factor which
results in increased transcription and MMP-1 production [25].
A single adenine insertion (6A) or deletion (5A) located at
position -1171 bp in the MMP-3 promoter region influences
MMP-3 expression by changing the affinity for repressor bind-
ing, with the 6A allele sequence having a stronger recognition
for the repressor binding site [23]. This also leads to enhanced
transcriptional levels and local MMP-3 production in the pres-
ence of the 5A allele [19]. In the MMP-9 gene, a C-to-T tran-
sition at -1306 bp results in an approximately 1.5-fold higher
promoter activity compared with the C allele [26].
Many studies have examined the association between epithe-
lial malignancy and MMP SNP status. Some have reported an
increased risk for breast cancer in women carrying the MMP-
3 5A allele [27,28], but this has not been confirmed in other
studies [29,30]. In others, the MMP-1 2G/2G genotype has
been associated with increased susceptibility to colorectal
cancer [20], though not to breast cancer. To date, as far as we
are aware, MMP-9 SNP status has not been related to cancer
susceptibility.
Although the evidence for a role of MMP SNPs in enhancing
susceptibility to breast cancer is somewhat equivocal, MMPs
have an established role in promoting tumor cell invasion
[19,31]. Thus, mechanisms leading to higher expression of
MMP might be expected to enhance tumor progression. To
date, no studies have investigated the influence of MMP SNP
genotype on the ability of the stromal environment to modulate
tumor behavior. This study has analyzed the ability of primary
breast fibroblasts, from patients with or without breast cancer,
to promote breast tumor cell invasion and has investigated the
relationship between MMP SNP status, donor group, and
fibroblast invasion-promoting capacity (IPC) by examining the
contribution of MMP activity to the invasive process.
Materials and methods
Breast tissue and cell lines
Breast tissue was obtained from women undergoing surgery
for breast carcinoma (n = 13; age range 37 to 85 years) or
reduction mammoplasty (n = 19; age range 19 to 54 years)
following informed consent and approval of the study by the
North East London Ethics Committee and the Leicestershire
and Rutland Ethics Committee. None of the patients had
received pre-operative chemotherapy. The breast cancer cell
line, MDA-MB 468, and the human fetal foreskin fibroblast cell
line, hfff2, were obtained from the American Type Culture Col-
lection (Manassas, VA, USA).
Isolation of primary fibroblasts
Tissue, excess to histopathological diagnosis, was selected
from the breast samples and fibroblasts were isolated as
described previously [32]. Briefly, the tissue was digested for
12 hours in Dulbecco's modified Eagle's medium (DMEM),
10% fetal bovine serum (FBS), 2 mM L-Glutamine, 100 IU
penicillin and streptomycin, 400 IU collagenase IA, and 65 IU
hyaluronidase (all reagents obtained from Sigma-Aldrich Com-
pany Ltd., Poole, Dorset, UK). Following a sedimentation step
at 1 g for 30 minutes, the supernatant was removed and cen-
trifuged, washed twice in serum-free DMEM, and then filteredAvailable online http://breast-cancer-research.com/content/9/5/R67
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through a 20-μm cell strainer (BDFalcon, San Diego, CA,
USA). The filtrate was spun down and the cell pellet resus-
pended in DMEM with 10% FBS, penicillin and streptomycin
(100 U/mL), and fungizone (2.5 μg/mL) (Gibco-BRL, now part
of Invitrogen Corporation, Carlsbad, CA, USA). The cells were
cultured for 24 hours, then the medium was aspirated off, and
the cells were washed with DMEM (to remove any non-viable
cells or contaminating red blood cells) before re-feeding with
complete DMEM. All experiments, including generation of con-
ditioned media (CM), were performed using fibroblasts that
had been passaged at 70% confluency a maximum of four
times after initial isolation.
Characterization of fibroblasts
Cells plated onto poly-L-lysine-coated coverslips were stained
with antibodies to vimentin (clone 384; Dako UK Ltd., Ely,
Cambridgeshire, UK), cytokeratin 14 (clone LL01, gift from EB
Lane, University of Dundee, UK), cytokeratin 18 (clone CY90;
Serotec Ltd., Oxford, Oxfordshire, UK), epithelial membrane
antigen (EMA) (clone E29; Dako UK Ltd.), CD31 (clone
JC70A; Dako UK Ltd.), CD45 (clone 2B11/PD7/26; Dako UK
Ltd.), alpha-smooth muscle actin (α-SMA) (clone 1A4; Dako
UK Ltd.), and α1 integrin (clone SR84; BD Pharmingen, San
Diego, CA, USA). Fluorescein isothiocyanate-conjugated rab-
bit anti-mouse F(ab1)2 was used as a secondary antibody, and
staining was recorded on a Zeiss Axiovert 200 M confocal
microscope using the LSM 510 Meta software (Carl Zeiss,
Jena, Germany). Omission of the primary antibody was
included as a negative control.
Generation of fibroblast conditioned medium
Fibroblasts were plated into 25-cm2 tissue culture flasks and
grown to 60% confluency, the media removed, cells washed
with Dulbecco's phosphate-buffered saline (dPBS), and 5 mL
of serum-free DMEM was added. Fibroblasts then were cul-
tured for a further 48 hours, and media were removed and cen-
trifuged to remove cell debris and stored at -80°C until use.
For the reproducibility assay, hfff2 cells were cultured in 75-
cm2 tissue culture flasks generating 15 mL of CM in order to
allow assays to be performed in triplicate.
Invasion assays
Two types of invasion assay were performed. In one, donor
fibroblasts were incorporated into the lower well of the inva-
sion assay (Fib co-culture assay), allowing crosstalk between
the fibroblast and tumor cell populations. In the other, CM,
generated from an equivalent number of fibroblasts, was
placed in the lower well of the invasion assay. The invasion
assays were carried out over the course of 48 hours as
described previously [32]. Briefly, the lower surface of an 8-
μm-pore polyethylene terephthalate track-etched membrane
was coated with 10 μg/mL fibronectin (Sigma-Aldrich Com-
pany Ltd.) and the upper surface was coated with Englebreth-
Holm-Swarm basement membrane (Matrigel; Becton, Dickin-
son and Company, Franklin Lakes, NJ, USA) at a final concen-
tration of 5 μg per filter. The upper membrane was seeded
with 5 × 104 MDA-MB-468 cells in serum-free DMEM, and
either 1 × 105 fibroblasts or fibroblast CM (1 mL) was placed
into the lower chamber. Invasion assays were set up in quad-
ruplicate, cell counts were performed on hematoxylin and
eosin-stained membranes, and an invasion index was calcu-
lated as a percentage of the number of cells on the lower
membrane compared with the total number of cells (on the
upper and lower membranes).
For invasion assays in which human recombinant MMP-3 was
included (R&D Systems Europe Ltd, Abingdon, Oxfordshire),
a range of MMP-3 concentrations (12.5 to 100 ng/mL) was
added at the start of the assay. For invasion assays incorporat-
ing inhibitors, 25 μM MMP-3 inhibitor (Ac-RCGVPD-NH2;
code number: 444218; Calbiochem, now part of EMD Bio-
sciences, Inc., San Diego, CA, USA) or vehicle control was
added at the beginning of the assay and again at 24 hours.
The assays then were processed as described above. At the
end of the invasion assay, medium from the four wells of the
assay was harvested (referred to as end-of-assay CM), centri-
fuged to remove cell debris, and stored at -80°C until use.
Analysis of MMP polymorphism status
Purification of genomic DNA from frozen fibroblast popula-
tions was carried out using the DNA Research Innovations Ltd
Genomic DNA purification kit (DNA Research Innovations Ltd,
Kent, UK) according to the manufacturer's instructions. Briefly,
approximately 250,000 cells in 100 μL of dPBS was lysed in
lysis buffer containing proteinase K for 5 minutes and DNA
was captured using magnetic beads with a DNA-binding pos-
itive charge. DNA was eluted from the beads using a low-salt
(10 mM Tris-HCl; pH 8.5) buffer. DNA concentration and
purity were assessed by means of a spectrophotometer.
Fibroblast populations from 19 normal donors and 13 patients
with breast cancer were analyzed. As an internal control for the
MMP polymorphism polymerase chain reaction (PCR), nine
paired dermal samples also were included in the study.
PCR was performed using 100 ng of DNA in each reaction
with the following primers: MMP-1 forward: TCG TGA GAA
TGT CTT CCC ATT, MMP-1 reverse: TCT TGG ATT GAT
TTG AGA TAA GTG AAA TC [32]; MMP-3 forward: GAT TAC
AGA CAT GGG TCA CA, MMP-3 reverse: TTT CAA TCA
GGA CAA GAC GAA GTT T [33]; and MMP-9 forward: GCC
TGG CAC ATA GTA GGC CC, MMP-9 reverse: CTT CCT
AGC CAG CCG GCA TC [34]. PCR products were digested
at 37°C for 18 hours using 1 U per reaction xml-1 (MMP-1
and MMP-3) or sphI (MMP-9) (New England Biolabs, Inc., Ips-
wich, MA, USA), and digestion products were analyzed using
agarose gel electrophoresis.
Measurement of MMP release and activity
Substrate gel zymography was carried out as described previ-
ously [35]. The end-of-assay CM was concentrated usingBreast Cancer Research    Vol 9 No 5    Holliday et al.
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Centricon centrifugal filter devices (YM-10; Millipore Corpora-
tion, Billerica, MA, USA) and 50 μg of protein mixed with 10×
non-reducing sample buffer (0.3 M Tris-HCL [pH 6.8], 12.5%
glycerol, 1% SDS, and 1% bromophenol blue). Samples were
run on a 12% polyacrylamide gel containing 0.01% SDS and
a final concentration of 1 mg/mL gelatin. Recombinant pro-
MMP-2 and pro-MMP-9 (Calbiochem) were included as
standards on each gel. Electrophoresis was carried out for 3
hours at 120 V before renaturation of proteins by three 15-
minute washes in 2.5% Triton X-100. Gels were incubated
overnight at 37°C in developing buffer (0.5 M Tris, 2 M NaCl,
0.05 M CaCl2, and 0.2% Triton X-100) and stained with 0.5%
Coomassie Blue. Gelatinolytic activity was visualized, as clear
bands on the uniformly blue-stained background, and quanti-
tated by densitometry. A sandwich enzyme immunoassay kit
(R&D Systems Europe Ltd, Abingdon, Oxfordshire) was used
to measure total MMP-3 present in end-of-assay CM and was
carried out according to the manufacturer's instructions.
RT-PCR analysis of MMP expression
To determine the cellular source of MMP, RNA was isolated
from cell populations and reverse transcription (RT)-PCR was
carried out for MMP-1, MMP-3, and the housekeeping gene
GAPDH. Total RNA was extracted using a standard phenol/
chloroform extraction procedure [36]. After quantitation, 1 μg
of total RNA was taken from each sample and cDNA was gen-
erated using the Promega Reverse Transcription kit according
to the manufacturer's instructions. PCR was carried out using
megamix reaction buffer (Microzone Limited, Haywards Heath,
West Sussex, UK), 1 μL of cDNA in each reaction, and 200
nM of primer. Primer sequences were as follows: GAPDH for-
ward: AGA ACA TCA TCC CTG CCT CC, GAPDH reverse:
GCC AAA TTC GTT GTC ATA CC; MMP-1 forward: CGA
CTC TAG AAA CAC AAG AGC AAG A, MMP-1 reverse:
AAG GTT AGC TTA CTG TCA CAC GCT T; and MMP-3 for-
ward: TCT GAA AGT CTG GGA AGA GGT C, MMP-3
reverse: CAG TGT TGG CTG AGT GAA AGA G. PCR prod-
ucts were analyzed on a 2% agarose gel.
Statistical analysis
Statistical analysis was performed using the SPSS 12.0 sta-
tistics package (SPSS Inc., Chicago, IL, USA). For compari-
son between normal breast and tumor donor samples, an
independent samples test was carried out. Odds ratios (ORs)
and 95% confidence intervals (CIs) were calculated as an
index of the association of genotype and donor group. For
comparison of within-donor variables, such as CM assay ver-
sus Fib assay and breast versus dermal IPC, a repeated-meas-
ures analysis-of-variance analysis was performed. All statistical
tests were two-sided, and a p value of less than 0.05 was con-
sidered significant.
Results
Isolation and characterization of fibroblasts
Fibroblasts were isolated from 32 donors: 13 with invasive
breast carcinoma and 19 with no breast pathology. In the
tumor donor cases, the fibroblasts were isolated from within
the carcinoma (that is, tumor-associated fibroblasts, or TAFs).
The purity of the fibroblast populations was confirmed by
immunostaining. The isolated cells (>95%) stained uniformly
for vimentin and were negative for the luminal epithelial-asso-
ciated EMA and CK18, the endothelial-associated CD31, and
the pericyte and vascular smooth muscle-related α1-integrin
(Figure 1a–e). The isolated cells also were negative for the leu-
kocyte marker CD45 (not shown). The majority of the cells
were negative for the myoepithelial-associated cytokeratin
CK14. However, approximately 1% of cells exhibited strong
staining for this cytokeratin (Figure 1f). A similar pattern of
reactivity was seen in the hfff2 cell line, suggesting that this
staining pattern does not represent contaminating myoepithe-
lial cells. Cell populations also were stained for α-SMA (Figure
1g) and this showed that approximately 35% of cells were
positive at passage 4 when they were used in experiments,
with no differences in populations discerned between TAFs
and normal breast fibroblasts (data not shown). Taken
together, the results indicate that the isolated fibroblast popu-
lations were substantially pure (>95%) and not contaminated
with epithelial, myoepithelial, endothelial, inflammatory, or per-
icyte cell populations.
Tumor-fibroblast interactions determine invasion-
promoting capacity
The reproducibility of the invasion assay was confirmed by
using the hfff2 fibroblasts, or CM from these fibroblasts, with
the MDA MB 468 breast cancer cell line in experiments con-
ducted on three separate days. The results demonstrate a high
level of reproducibility between assays with mean invasions of
22.2% (± 0.6%) in the CM assay and 28.4% (± 0.4%) in the
fibroblast co-culture assay (Figure 2). The higher level of inva-
sion generated in the co-culture assay, though modest in
absolute terms, statistically was highly significant (p = 0.001)
and suggests that the concomitant presence of fibroblasts is
more stimulatory for invasive activity than conditioned medium
alone.
Fibroblasts from normal breast were compared with fibrob-
lasts from carcinomas in order to determine whether they had
differing effects on stimulating tumor cell invasion. As shown
in Figure 3, when the normal fibroblasts (n = 8) were used to
create CM (as compared to the tumor fibroblasts; n = 8) and
then assessed for stimulation of tumor cell invasion, there was
variability between individual donors (Figure 3a). However, the
mean percentage of tumor invasion was 7.7% (range 2.9% to
16.2%) after treatment with CM from normal fibroblasts versus
15.2% (range 3.8% to 24.3%) with CM from tumor fibroblastsAvailable online http://breast-cancer-research.com/content/9/5/R67
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(Figure 3b). These values were statistically different (p  =
0.009) and indicate that CM from tumor-derived fibroblasts
has a higher intrinsic IPC than CM from normal fibroblasts.
When fibroblasts were co-cultured with the tumor cells, con-
siderable variability again was demonstrated between individ-
ual donors (Figure 3c). As in the reproducibility assays (Figure
2) for both normal fibroblasts and tumor-derived fibroblasts,
higher levels of tumor invasion were generated in the presence
of the fibroblast populations compared with CM (Figure 3b,d),
with a mean invasion generated by normal fibroblasts of
15.8% (range 9.1% to 23.6%) compared with 7.7% (range
2.9% to 16.2%) with CM (p ≤ 0.001) and with a mean invasion
of tumor-derived fibroblasts of 24.0% (range 13.3% to
37.1%) compared with 15.2% (range 3.8% to 24.3%) with
CM (p  = 0.02). In both the CM assay and the co-culture
assays, the presence of tumor fibroblasts generated signifi-
cantly higher IPC than normal fibroblasts (p = 0.02) (Figure
3c,d). Since, physiologically, fibroblasts maintain interactions
with the tumor cells, the fibroblast co-culture assays were
used for further analysis.
Tumor-derived fibroblast IPC, but not normal fibroblast 
IPC, relates to MMP polymorphism status
To assess the relationship between fibroblast IPC and MMP
polymorphism status, donor DNA (n = 32) was analyzed for
functional SNPs in MMP-1, MMP-3, and MMP-9 genes. The
Figure 1
Characterization of isolated fibroblast populations Characterization of isolated fibroblast populations. Isolated breast fibroblast populations were characterized by immunofluorescent staining. All cells 
exhibited staining for vimentin (a) but were uniformly negative for the luminal epithelial membrane antigen (b), cytokeratin 18 (c), the endothelial-
associated CD31 (d), and pericyte-related α1-integrin (e). Approximately 1% of cells stained strongly for cytokeratin 14 (f, inset), and approximately 
35% of cells were positive for alpha-smooth muscle actin (g). (h) Negative control.
Figure 2
Reproducibility of invasion assays Reproducibility of invasion assays. Conditioned media (CM) and fibro-
blast co-culture invasion assays with the MDA MB 468 breast cancer 
cell line were carried out in triplicate on three separate days. A high 
level of reproducibility was obtained between experiments. The two dif-
ferent types of assay demonstrate significantly different levels of inva-
sion, with higher tumor invasion in the presence of fibroblasts 
compared with CM alone (p = 0.001).Breast Cancer Research    Vol 9 No 5    Holliday et al.
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analysis was performed both on breast fibroblasts and on iso-
lated skin fibroblasts in order to confirm genotype and exclude
false calls resulting from possible loss of heterozygosity. In all
cases, there was concordance between breast and skin DNA,
and genotype was confirmed by sequencing (data not shown).
When genotype status was compared with donor type, no sig-
nificant difference in SNP status for MMP-1, MMP-3, or MMP-
9 was seen in tumor donors versus non-tumor donors (Figure
4), although there was a trend toward higher frequency of the
MMP-3 5A/5A genotype amongst the breast cancer donor
group, with the OR of relative risk associated with 5A/5A com-
pared to the other two genotypes being 3.21 (95% CI 0.68 to
15.16; p = 0.14).
When MMP SNP status was compared to normal fibroblast
IPC, no relationship was observed between genotype and
IPC. However, in tumor-derived fibroblasts, there was an
inverse relationship with MMP-1 genotype, with lower levels of
invasion generated by donors with the high-expressing 2G/2G
genotype compared with the 1G/2G or 1G/1G genotypes (p
= 0.08 and 0.03, respectively) (Figure 4a.ii). Furthermore,
tumor donors with the high-expressing MMP-3 5A/5A geno-
type exhibited higher IPC compared with 6A/5A and 6A/6A
donor genotypes, (p = 0.05 and 0.07, respectively) (Figure
4b.ii), although no relationship was demonstrated between
MMP-9 genotype and donor IPC (Figure 4c.ii). Significantly
higher invasion was promoted by tumor fibroblasts with the
MMP-1 1G/1G genotype compared with their normal counter-
parts (p = 0.025) (Figure 4a.ii) and, similarly, tumor fibroblasts
with the MMP-3 5A/5A genotype demonstrated significantly
higher IPC than normal fibroblasts with the same genotype (p
= 0.04) (Figure 4b.ii). Donor numbers were too small to carry
out formal linkage analysis. However, 6 of 10 donors with the
Figure 3
Relationship between fibroblast invasion-promoting capacity and donor type Relationship between fibroblast invasion-promoting capacity and donor type. Conditioned media (CM) (i) and fibroblast co-culture (ii) invasion 
assays were carried out comparing eight normal donors and eight tumor donors. Graphs (a) and (c) show scatterplots of individual donors, and (b) 
and (d) illustrate mean invasion generated by the two donor groups. In the CM assay, significantly higher levels of tumor invasion were generated by 
CM from tumor-derived fibroblasts compared with normal fibroblasts (b) (p = 0.009). Higher levels of invasion were generated in the fibroblast co-
culture assays compared with the CM assay for both normal (p ≤ 0.001) and tumor-derived (p = 0.02) fibroblasts (b,d), and a significant difference 
between normal and tumor-derived fibroblast invasion-promoting capacity was demonstrated in the co-culture assay (d) (p = 0.039). * p =< 0.05.Available online http://breast-cancer-research.com/content/9/5/R67
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Figure 4
Relationship between fibroblast matrix metalloproteinase (MMP) polymorphism status and (i) donor type and (ii) invasion-promoting capacity Relationship between fibroblast matrix metalloproteinase (MMP) polymorphism status and (i) donor type and (ii) invasion-promoting capacity. Donors 
(n = 19 normal, 13 tumor) were analyzed for MMP-1 (a), MMP-3 (b), and MMP-9 (c) polymorphism status. No significant relationship was identified 
between MMP genotype and donor type (i), although a trend toward increased frequency of the MMP-3 5A/5A genotype is observed in the breast 
cancer donor group (a.i). When compared to fibroblast invasion-promoting capacity, higher tumor invasion was generated by donors with the MMP-
1 1G/1G genotype compared with the 1G/2G and 2G/2G genotype (a.ii) (p = 0.08 and 0.032, respectively), and significantly higher invasion was 
promoted by tumor fibroblasts with the 1G/1G genotype compared with normal donors with the same genotype (p = 0.025). In addition, higher inva-
sion was stimulated by fibroblasts with the MMP-3 5A/5A genotype compared with the 5A/6A or 6A/6A genotypes (b.ii) (p = 0.05 and 0.07, 
respectively), and significantly higher invasion was promoted by tumor donors with the 5A/5A genotype when compared with normal donors with the 
same genotype (p = 0.04). No relationship was identified between MMP-9 genotype and invasion-promoting capacity (c.ii). * p =< 0.05Breast Cancer Research    Vol 9 No 5    Holliday et al.
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MMP-3  5A/5A genotype also carried the MMP-1  1G/1G
genotype.
MMP-3 polymorphism status in relation to MMP 
expression and activation
The level of MMP-3 release in relation to SNP genotype was
measured by enzyme-linked immunosorbent assay of end-of-
assay CM. This indicated that tumor fibroblasts with the 5A/5A
genotype secreted more MMP-3 than tumor fibroblasts with
either the 6A/5A or 6A/6A genotypes (p = 0.07 and 0.009,
respectively). In addition, tumor fibroblasts with the 5A/5A
genotype were associated with significantly higher levels of
MMP-3 release than normal fibroblasts with the 5A/5A geno-
type (p = 0.028) (Figure 5a) and this correlated also with a
high IPC phenotype (Figure 5b).
Since MMP-3 can activate other MMPs involved in mediating
tumor invasion, including MMP-9, the relationship between
MMP-3 genotype, IPC, and gelatinase levels in end-of-assay
CM was analyzed. No correlation was identified between
MMP-2 or MMP-9 gelatinase levels and IPC or MMP-3 status
(Figure 5c).
Contribution of fibroblast-derived MMP-3 activity to 
tumor cell invasion
In situ hybridization studies suggest that the major source of
MMPs in breast cancer is constituted by the stromal compart-
ment [20,37]. To confirm that fibroblasts are the source of
MMP in the current invasion assay systems, RT-PCR was car-
ried out on the MDA MB 468 tumor cells cultured alone or fol-
lowing culture with fibroblast CM, and on primary breast
fibroblasts and the hfff2 fibroblast cell line. This showed that
the MDA MB 468 tumor cells used in the invasion assays in
this study do not express MMP-1 or MMP-3, even following
culture with fibroblast CM, whereas the fibroblast populations
express both of these MMPs (Figure 6a).
Figure 5
Relationship between matrix metalloproteinase-3 (MMP-3) polymorphism status and MMP release and activation Relationship between matrix metalloproteinase-3 (MMP-3) polymorphism status and MMP release and activation. (a) Relationship between MMP-3 
genotype and total MMP-3 release into end-of-assay conditioned media. The tumor fibroblast 5A/5A genotype is associated with higher levels of 
MMP-3 release compared with the tumor fibroblast 6A/5A genotype (p = 0.07) and the 6A/6A genotype (p = 0.009). Additionally, tumor fibroblasts 
with the 5A/5A genotype release significantly higher levels of MMP-3 than normal fibroblasts with this genotype. (b) Relationship between MMP-3 
genotype, invasion-promoting capacity (IPC), and MMP-3 release. For tumor fibroblasts, there was a correlation between MMP-3 5A/5A genotype, a 
high IPC phenotype, and high MMP-3 release. (c) Relationship between MMP-3 genotype and (i) pro-MMP-2 and (ii) pro-MMP-9 levels measured by 
zymography. No significant association between genotype and gelatinolytic activity in normal or tumor fibroblasts was identified. Abs, antibodies. * p 
=< 0.05Available online http://breast-cancer-research.com/content/9/5/R67
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Contribution of MMP-3 activity to tumor cell invasion
To determine the contribution made by MMP-3 activity to
tumor cell invasion, the invasion assays were carried out in the
absence of MMP-3 (control) or the addition of a range of con-
centrations of human recombinant MMP-3. The concentra-
tions used were determined by the levels of endogenous
MMP-3 detected from the primary fibroblast cultures. The data
demonstrated an incremental increase in tumor cell invasion
Figure 6
Contribution of fibroblast-derived matrix metalloproteinase-3 (MMP-3) activity to tumor cell invasion Contribution of fibroblast-derived matrix metalloproteinase-3 (MMP-3) activity to tumor cell invasion. (a) Reverse transcription-polymerase chain 
reaction for housekeeping gene GAPDH, MMP-1, and MMP-3 in tumor cell and fibroblast populations, indicating that MDA MB 468 tumor cells do 
not express MMP-1 or MMP-3, even following culture with fibroblast conditioned media (CM), whereas both primary fibroblasts and the hfff2 cell line 
are a source of these MMPs. (1) MDA MB 468; (2) MDA MB 468 + fibroblast CM; (3) hfff2 fibroblast cell line; (4) primary fibroblasts; (5) water 
blank. M, molecular weight markers. (b) Effect of human recombinant MMP-3 on invasion of MDA MB 468 cells. Increasing invasion is observed in 
the presence of increasing concentrations of MMP-3, with a doubling of invasion at 100 ng/mL MMP-3 compared with control (p = 0.014). (c) Effect 
of the MMP-3 inhibitor on fibroblast-stimulated tumor invasion: (i) shows tumor invasion generated by three separate donors, and (ii) shows mean 
invasion in the presence of MMP-3 inhibitor relative to control. There is a significant reduction in tumor cell invasion in the presence of MMP-3 inhib-
itor (p = 0.005). * p =< 0.05.Breast Cancer Research    Vol 9 No 5    Holliday et al.
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with increasing concentration of MMP-3 (Figure 6b), with a
doubling of invasion in the presence of 100 ng/mL MMP-3
compared with control (p = 0.014). To demonstrate the con-
tribution of fibroblast-derived MMP-3, co-culture invasion
assays were carried out in the presence of the specific MMP-
3 inhibitor, Ac-RCGVPD-NH2. This revealed a consistent and
highly significant reduction in tumor cell invasion in the
presence of the MMP-3 inhibitor compared with vehicle-only
control assays (p = 0.005) (Figure 6b), thus supporting a role
for fibroblast-derived MMP-3 activity in promoting tumor cell
invasion.
Discussion
There is increasing recognition of the importance of the micro-
environment in modulating tumor cell behavior [1,2,38], partic-
ularly of the role of fibroblasts in this process [5,9]. MMPs
could play a multifaceted role in such a phenomenon, modify-
ing the tumor microenvironment through direct breakdown of
matrix proteins and basement membrane barriers, promotion
of angiogenesis, and/or the release and activation of growth
factors [18]. Both MMP-1 and MMP-3 have been shown to
affect the motility and invasion of tumor cells directly [39,40].
Therefore, differences in the capacity to express MMPs may
be critical in regulating tumor behavior. One of the mecha-
nisms by which MMP expression could be modified is through
the existence of functional SNPs capable of influencing gene
promoter activity [23-26]. Several studies have examined the
association between MMP SNP genotype and the prevalence
of breast cancer [27-30], but directly relating such intrinsic
characteristics to cellular behavior is difficult owing to the chal-
lenge of isolating primary cells for functional studies from a
large enough group of donors. This is the first study to use
purified cell populations from different donor groups in order
to investigate the impact of MMP SNP genotype on tumor cell
behavior. Since the major source of MMPs in breast cancer is
the stromal fibroblast [20,22,37], we examined the relation-
ship between MMP SNP genotype and the ability of donor
fibroblasts to promote breast cancer cell invasion. The data
show that, whereas fibroblasts from different donors vary in
their capacity to promote tumor invasion, significantly higher
levels of tumor invasion are generated by tumor fibroblasts
compared with normal fibroblasts, results in keeping with pre-
vious studies [2,17,41]. This was seen both in CM and fibro-
blast co-culture assays, although the level of tumor invasion
was higher in the presence of fibroblasts, indicating a role for
tumor-fibroblast interactions in determining tumor behavior.
When fibroblast IPC was related to MMP SNP genotype, we
identified a significant association between the high-express-
ing MMP-3 5A/5A genotype and high IPC of donor fibroblasts
for the tumor-derived populations, though not in the normal
fibroblast donors. Thus, whereas tumor-derived fibroblasts of
MMP-3 5A/5A status exhibited significantly higher invasion
than tumor fibroblasts of 5A/6A or 6A/6A status, the IPC of
normal fibroblasts of MMP-3 5A/5A genotype did not differ
from fibroblasts of 5A/6A or 6A/6A status. Furthermore, the
MMP-3 5A/5A genotype and high IPC were reflected in higher
levels of MMP-3 activity in tumor-derived fibroblasts, although
the normal donor fibroblasts of MMP-3 5A/5A genotype did
not exhibit enhanced MMP-3 activity. This suggests that
tumor-derived fibroblasts have undergone additional changes
that influence the phenotypic expression of the MMP SNP
genotype and that the high IPC of tumor-derived fibroblasts is
not simply a response to tumor-derived signals. It previously
has been demonstrated that the tumor-promoting capacity of
tumor fibroblasts is a stable feature of this population [2], and
there are several reports of distinct genetic and epigenetic
changes in TAFs [13-15]. It is plausible that epigenetic altera-
tions, such as demethylation (which is common in tumors
[42]), may unmask the high-expressing potential of the MMP-
3  5A/5A genotype in tumor fibroblasts. Despite previous
reports of the wide variation in expression detected in relation
to SNPs [43,44], in our study the MMP-3 5A/5A genotype
was reflected in significantly higher levels of MMP-3 release in
patients with breast cancer compared with the 5A/6A geno-
type, with the difference not quite reaching significance for the
6A/6A genotype group.
In apparent contradiction to the predicted enhancing role of
MMPs, there was an inverse relationship between the high-
expressing MMP-1 2G/2G genotype and invasion. This possi-
bly reflects the nature of the invasion barrier used in these
assays; thus, we measured invasion through basement mem-
brane, which would be degraded by MMP-3, rather than inva-
sion through interstitial collagen, which would be more
dependent on MMP-1 activity. Alternatively, the inverse rela-
tionship between IPC and the high-expressing MMP-1 2G/2G
genotype may reflect linkage disequilibrium between the
MMP-1 2G and MMP-3 6A alleles as has been reported in
colorectal cancer [24]. The number of donors in this study,
though large in comparison to other studies, was too small to
perform linkage analysis, but the results do suggest a relation-
ship between MMP-1 2G and MMP-3 6A, and formal analysis
on a larger patient cohort currently is being undertaken.
Perhaps different MMPs are important at different stages of
disease progression and the models used here are more rep-
resentative of early-stage invasion. The importance of MMP-3
at this initial stage of invasion is reflected in animal models in
which targeting overexpression of MMP-3 to normal mouse
mammary glands has been shown to induce an altered stromal
environment promoting the phenotypic conversion and malig-
nant transformation of mammary epithelial cells [45,46]. More-
over, MMP-3, in addition to other MMPs, has been implicated
in Wnt1-induced mouse mammary tumorigenesis [22]. Such
results are consistent with the possibility that MMP-3 expres-
sion may be important in the initiation of breast cancer. The
functional importance of MMP-3 activity was demonstrated by
a significant reduction in tumor cell invasion in the presence of
a selective MMP-3 inhibitor. Crucially, our results indicate aAvailable online http://breast-cancer-research.com/content/9/5/R67
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stronger relationship between fibroblast IPC and MMP-3 gen-
otype than the fibroblast IPC and donor status since, in our
system, tumor-derived fibroblasts of MMP-3 5A/6A or 6A/6A
genotype did not differ in their IPC from normal fibroblasts.
Thus, while tumor-derived fibroblasts are stimulatory of tumor
invasion, whether or not they are of the MMP-3 5A/5A geno-
type is more important.
Evidence for a role for MMP-3 in breast cancer comes from tis-
sue studies and animal models. MMP-3  expression is
detected in the stroma around invasive breast tumors
[20,22,47] and is an indicator of poor prognosis [21]. Interest-
ingly, our study showed that fibroblasts derived from patients
with breast cancer were more frequently of the 5A/5A geno-
type compared with normal fibroblasts and, together, this sup-
ports a previous study suggesting an association between the
MMP-3  5A SNP and breast cancer susceptibility [27],
although two subsequent studies failed to find such an
association [28,29]. All three studies, however, found an asso-
ciation with lymph node positivity in patients with breast can-
cer, which we interpret as being consistent with our findings
of a direct involvement of MMP-3 in tumor invasion promotion.
As well as degrading a wide spectrum of matrix proteins,
MMP-3 activates other MMPs, including MMP-9 [48]. This
could further enhance tumor invasion. However, no clear or
significant relationship between MMP-3  SNP status and
MMP-3 release with MMP-9 gelatinolytic levels was identified
in this study.
Conclusion
This study has shown that tumor-fibroblast-derived MMP-3
release, associated with the MMP-3  5A/5A genotype,
enhances tumor invasion, and it suggests that women with this
genotype may suffer from enhanced tumor progression. This
report emphasizes the importance of microenvironmental fac-
tors – and the intrinsic characteristics of the host microenvi-
ronment – in cancer evolution.
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